Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | CHIEF LEGAL OFFICER | February 11, 2026 | February 13, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | GC & Chief Compliance Officer | February 01, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,835 |
Ending reported balance
After 2026-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-11 · Exercise / conversion · Acquired 10,000 · Balance 22,835 Row 2 · 2026-02-11 · Sale · Disposed 10,000 · Balance 12,835 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.70 · Expires 2031-02-09 | Direct | 35,000 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Exercise / conversion · Disposed 10,000 · Balance 35,000 F2: The stock option is fully vested. F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
F2: The stock option is fully vested.
F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.
OTONOMY, INC.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.80 · Expires 2028-01-31 | Direct | 110,000 |
Reported balance
After 2018-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-01 · Grant · Acquired 110,000 · Balance 110,000 F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter. F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter.
F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 21, 2024 17:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0001415889-24-004666 · form4-02212024_100259.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,240 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated September 15, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 17:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,000 | $14.02 | $70,100.00 |
DisclosureSEC source: 0001415889-24-004666 · form4-02212024_100259.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 19:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,305 | $21.81 | $50,272.05 |
DisclosureSEC source: 0001209191-24-001279 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,240 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 19:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001279 · doc4.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,635 Underlying: Common Stock · 5,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 19:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001279 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:55 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 29,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001047 · doc4.xml · derivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,150 Underlying: Common Stock · 29,150 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:55 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 79,780 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001047 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,780 Underlying: Common Stock · 79,780 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 16:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 882 | $14.19 | $12,515.58 |
DisclosureSEC source: 0001209191-23-056638 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated September 29, 2022, as amended February 21, 2023. F2 · shares: The shares sold represent 882 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on November 16, 2022 and the closing price of May 15, 2023. Read SEC document |
| September 18, 2023 Filed Sep 18, 2023 18:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,895 | $19.32 | $75,232.31 |
DisclosureSEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882 F4 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.135 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 18:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049809 · doc4.xml · derivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 18:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,105 | $19.48 | $41,005.40 |
DisclosureSEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,777 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 18:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Reflects the acquisition of 882 shares acquired under the Company's ESPP. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 19:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 22,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002881 · doc4.xml · derivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,180 Underlying: Common Stock · 22,180 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 19:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 60,530 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002881 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,530 Underlying: Common Stock · 60,530 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 17:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050351 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents a one-time retention grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 12,000 shares of common stock as set forth in Table II above, the Reporting Person also holds an additional options to purchase up to an aggregate of 308,000 shares of common stock, which options vest according to their terms. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 18:03 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 523 | $25.00 | $13,075.00 |
DisclosureSEC source: 0001209191-22-045061 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The shares sold represent 523 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on November 15, 2021. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 19:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-22-039532 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award. F2 · balance_after: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 298,000 shares of common stock, which options vest according to their terms, and (ii) 523 shares of common stock held directly. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 17:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-22-036020 · doc4.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 2,500 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 83,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 215,000 shares of common stock, which options vest according to their terms. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 17:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,500 | $24.00 | $60,000.00 |
DisclosureSEC source: 0001209191-22-036020 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 17:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 2,500 | $14.02 | $35,050.00 |
DisclosureSEC source: 0001209191-22-036020 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 20, 2022 16:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,146 | $20.50 | $23,493.00 |
DisclosureSEC source: 0001209191-22-031028 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The shares sold represent 1,146 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on May 13, 2022 and November 16, 2022. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 16:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009335 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2 · balance_after: In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 230,500 shares of common stock, which options vest according to their terms, and (ii) 523 shares of common stock held directly. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 17:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 523 | $22.03 | $11,521.69 |
DisclosureSEC source: 0001209191-21-065168 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523 F1 · shares: Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021. F2 · balance_after: In addition to the reporting person's common stock directly held as set forth in Table I above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 230,500 shares of common stock, which options vest according to their terms. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-21-063260 · doc4.xml · derivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2030-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-21-063260 · doc4.xml · derivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 Underlying: Common Stock · 2,500 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F3 · balance_after: In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,000 | $35.00 | $175,000.00 |
DisclosureSEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 2,500 | $20.16 | $50,400.00 |
DisclosureSEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 2,500 | $14.02 | $35,050.00 |
DisclosureSEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-21-010517 · doc4.xml · derivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 10,000 shares Expires 2029-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F4 · balance_after: In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0001209191-21-010517 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $14.02 | $140,200.00 |
DisclosureSEC source: 0001209191-21-010517 · doc4.xml · nonDerivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010517 · doc4.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 17:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-20-042506 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-07-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 17:40 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 98,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-19-059924 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · General Counsel & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2029-12-05 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 18, 2019 Filed Aug 20, 2019 17:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $49.20 | $0.00 |
DisclosureSEC source: 0001209191-19-046820 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · General Counsel & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2029-08-17 F1 · derivative.exercise_date: The option vests over a 4 year period: 25% vest and become exercisable on August 18, 2020, after which 1/48th of the total shares vest and become exercisable monthly thereafter, subject to reporting person's continuous service through each vesting date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 17:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009028 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 17:56 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $78.18 | $0.00 |
DisclosureSEC source: 0001209191-18-045892 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-08-05 F1 · derivative.exercise_date: The option vests over a 4 year period: 25% vest and become exercisable on August 6, 2019, after which 1/48th of the total shares vest and become exercisable monthly thereafter, subject to reporting person's continuous service through each vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:38 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-18-007610 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter. F2 · balance_after: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantEmployee Stock Option (right to buy) · Derivative | 33,333 | Not disclosed Strike: $5.68 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires 2026-01-18 F6 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 50,000 shares of common stock granted to the Reporting Person on March 6, 2017. In exchange, the Reporting Person received an option grant for 33,333 shares of common stock with exercise price of $5.675 per share. F9 · derivative.exercise_date: Of the 33,333 total shares subject to the option, 11,111 shares vest on January 19, 2019. Of the remaining 22,222 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantEmployee Stock Option (right to buy) · Derivative | 46,666 | Not disclosed Strike: $5.68 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,666 Underlying: Common Stock · 46,666 shares Expires 2026-01-18 F4 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 70,000 shares of common stock granted to the Reporting Person on March 1, 2016. In exchange, the Reporting Person received an option grant for 46,666 shares of common stock with exercise price of $5.675 per share. F8 · derivative.exercise_date: Of the 46,666 total shares subject to the option, 27,222 shares vest on January 19, 2019. Of the remaining 19,444 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantEmployee Stock Option (right to buy) · Derivative | 66,666 | Not disclosed Strike: $5.68 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2026-01-18 F2 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 100,000 shares of common stock granted to the Reporting Person on May 15, 2015. In exchange, the Reporting Person received an option grant for 66,666 shares of common stock with exercise price of $5.675 per share. F7 · derivative.exercise_date: Of the 66,666 total shares subject to the option, 52,777 shares vest on January 19, 2019. Of the remaining 13,889 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2027-03-05 F6 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 50,000 shares of common stock granted to the Reporting Person on March 6, 2017. In exchange, the Reporting Person received an option grant for 33,333 shares of common stock with exercise price of $5.675 per share. F5 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 6, 2018 and one forty-eighth (1/48) of the shares vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 70,000 | Not disclosed Strike: $14.44 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2026-02-28 F4 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 70,000 shares of common stock granted to the Reporting Person on March 1, 2016. In exchange, the Reporting Person received an option grant for 46,666 shares of common stock with exercise price of $5.675 per share. F3 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 1, 2017 and one forty-eighth (1/48) of the shares vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:34 UTC | OTONOMY, INC. OTIC · Entity 116495 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $31.59 | Not disclosed |
DisclosureSEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-05-14 F2 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 100,000 shares of common stock granted to the Reporting Person on May 15, 2015. In exchange, the Reporting Person received an option grant for 66,666 shares of common stock with exercise price of $5.675 per share. F1 · derivative.exercise_date: One-fourth (1/4) of the total number of shares initially subject to the option vest on May 15, 2016, and one forty-eighth (1/48) of the shares vest monthly thereafter. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 17:09 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 1,206 | $18.75 | $22,612.50 |
DisclosureSEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 6 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 17:09 UTC | OTONOMY, INC. OTIC · Entity 116495 | SaleCommon Stock | 2,316 | $18.50 | $42,846.00 |
DisclosureSEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 5 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2017 Filed Jun 27, 2017 17:09 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantCommon Stock | 1,206 | $11.43 | $13,784.58 |
DisclosureSEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 4 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,522 F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:18 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019334 · doc4.xml · derivative · entry 1 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 6, 2018 and one forty-eighth (1/48) of the shares vest monthly thereafter. F2 · balance_after: In addition to the option to purchase 50,000 shares of common stock as set forth on Table II, the Reporting Person currently holds options to purchase up to an aggregate of 170,000 shares of common stock, which options vest according to their terms. Read SEC document |
| December 01, 2016 Filed Jun 27, 2017 17:09 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantCommon Stock | 647 | $13.05 | $8,443.35 |
DisclosureSEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 3 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,316 F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 01, 2016 Filed Jun 27, 2017 17:09 UTC | OTONOMY, INC. OTIC · Entity 116495 | GrantCommon Stock | 1,021 | $13.13 | $13,405.73 |
DisclosureSEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 2 LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,669 F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.